1. Achieving Lipid Targets With PCSK9 Inhibition

4. Achieved LDL < 50 mg/dL Has a Greater Relative Risk Reduction Than Higher Levels

5. IMPROVE-IT Efficacy

7. ODYSSEY HIGH FH

8. Alirocumab and Evolocumab European Labelling and Indications

9. Alirocumab and Evolocumab US Labelling and Indications

10. GAUSS-2 Study of Evolocumab in Statin-Intolerant Patients % Change in LDL-C From Baseline at Week 12

11. Statin Myopathy is a Common Challenge in Lipid Management

12. Therapy for Statin Intolerance

13. Long-term Outcomes of Lipid-Lowering in FH

14. FH Starts Before Birth

15. Efficacy and Safety of Alirocumab in Individuals With Diabetes

16. New Onset Diabetes Mellitus (NODM) in IMPROVE-IT

17. Alirocumab Effect on Glycemic Measures in Patients Without Diabetes

18. PCSK9 Knockdown by RNAi

20. dal-OUTCOMES Dalcetrapib Did Not Reduce Risk of Recurrent CV Events

22. Abbreviations

23. Abbreviations (cont)